Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Result s: The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Background/Aims The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains largely uncertain. We aimed to explore the impact of DAA therapy on overall survival (OS) in HCC patients using a nationwide cohort study.
Methods We utilized the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) database to include all adults receiving a DAA therapy for HCV, excluding those with other viral infections, liver transplantation, non-HCC malignancies, and terminal-staged HCC. We respectively analyzed the adjusted odds ratio (aOR) for sustained virological response (SVR) and adjusted hazard ratio (aHR) for OS.
Result s: Between December 2013 and December 2020, 2,205 (9.3%) patients with HCC and 21,569 (90.7%) patients without HCC were include. The SVR rates were 96.6% in the HCC group and 98.8% in the non-HCC group (P<0.001), with HCC being an independent risk factor affecting SVR (aOR 0.41; 95% CI 0.31–0.54; P<0.001). In the whole patient cohort, SVR was independently associated with improved OS (aHR 0.46; 95% CI 0.35–0.60; P<0.001). Among patients with baseline HCC, SVR remained an independent factor related to OS (aHR 0.41; 95% CI 0.28–0.59; P<0.001). The impact of SVR on OS persisted significantly across BCLC stages 0/A and stages B/C.
Conclusions High SVR rates among HCC patients underscore the importance of DAA therapy in enhancing OS, reaffirming its efficacy across various HCC stages.
Citations
Citations to this article as recorded by
Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study” Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu Clinical and Molecular Hepatology.2026; 32(1): e99. CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study” Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu Clinical and Molecular Hepatology.2026; 32(1): e68. CrossRef
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai European Journal of Cancer.2026; 232: 116109. CrossRef
Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study” Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen Clinical and Molecular Hepatology.2026; 32(1): e7. CrossRef
Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC María Fernanda Guerra‐Veloz, Sital Shah, Beatrice Emmanouil, Mia Olsen, Renita George, Sarah Selemani, Paul J. Ross, Ivana Carey, Neha Mehta, Mark Gillyon‐Powell, Kosh Agarwal Journal of Viral Hepatitis.2026;[Epub] CrossRef
HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review Khumbuzile Canham, Pragalathan Naidoo, Sibusiso Senzani, Sayed Shakeel Kader, Zilungile L. Mkhize-Kwitshana Microorganisms.2025; 13(12): 2753. CrossRef
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Hepatitis C virus and cardiovascular disease: Current knowledge and unmet needs Chih-Wen Wang, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang Tzu Chi Medical Journal.2025; 37(4): 371. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Background/Aims Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.
Methods We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.
Result s: There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) decreased, whereas HDL-C (49.1 mg/dL vs. 51.9 mg/dL, P<0.001) and triglycerides (102.8 mg/dL vs. 111.9 mg/dL, P<0.001) increased significantly. The proportion of patients with SLD was 37.5% after HCV eradication, which did not change significantly compared with the pretreatment status. The percentage of the patients who had post-treatment MASLD was 34.8%, which did not differ significantly from the pretreatment status (P=0.17). Body mass index (BMI) (odds ratio [OR] 0.89; 95% confidence intervals [CI] 0.85–0.92; P<0.001) was the only factor associated with MASLD resolution. In contrast, unfavorable CMRFs, including BMI (OR 1.10; 95% CI 1.06–1.14; P<0.001) and HbA1c (OR 1.19; 95% CI 1.04–1.35; P=0.01), were independently associated with MASLD development after HCV cure.
Conclusions HCV eradication mitigates MASLD in CHC patients. CMRF surveillance is mandatory for CHC patients with metabolic alterations, which are altered after HCV eradication and predict the evolution of MASLD.
Citations
Citations to this article as recorded by
Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply Pei‐Chien Tsai, Jee‐Fu Huang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program” Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu Journal of the Formosan Medical Association.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and its associated health risks Xia-Rong Liu, Szu-Ching Yin, Yi-Ting Chen, Mei-Hsuan Lee Journal of the Chinese Medical Association.2025; 88(5): 343. CrossRef
Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea Beom Kyung Kim Gut and Liver.2025; 19(5): 635. CrossRef
Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis Ana Virseda-Berdices, Belen Requena, Juan Berenguer, Juan Gónzalez-García, Carolina Gonzalez-Riano, Cristina Díez, Victor Hontañón, Paula Muñoz-García, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, Rubén Martín-Escolano, María Ángeles Jiménez Journal of Infection and Public Health.2025; 18(12): 102981. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Steatotic liver disease in patients with chronic hepatitis C Jakub Janczura, Michał Brzdęk, Robert Flisiak, Krystyna Dobrowolska, Kinga Brzdęk, Piotr Rzymski, Dorota Zarębska-Michaluk World Journal of Hepatology.2025;[Epub] CrossRef
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Clin Mol Hepatol 2024;30(3):375-387. Published online March 26, 2024
Background/Aims Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAgpositive or -negative chronic HBV infection.
Methods Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twenty-five patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days.
Result s: A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths.
Conclusions In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.
Citations
Citations to this article as recorded by
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fu-Sheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon-Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei-Jer Chen, Hong You, Ming Hepatology International.2025; 19(4): 773. CrossRef
Mise à jour concernant le traitement des hépatites virales Marie Ongaro, Francesco Negro Schweizer Gastroenterologie.2025; 6(2): 46. CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients” Hae Lim Lee, Jeong Won Jang Clinical and Molecular Hepatology.2024; 30(4): 692. CrossRef
Background/Aims Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients.
Methods This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks.
Result s: 68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1–2, and no linvencorvir-related serious adverse events were reported.
Conclusions 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.
Citations
Citations to this article as recorded by
Current status and challenges of therapeutic targets, novel drugs and delivery systems for hepatitis B: how far to our goal? Yanmei Liao, Fei Lv, Mei Zhou, Jie Shen, Tianwen Quan Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Hepatitis B virus infection and its treatment in Eastern Ethiopia Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai World Journal of Hepatology.2025;[Epub] CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein International Journal of Molecular Sciences.2025; 26(8): 3633. CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
HBc: the multifunctional architect of HBV replication, immune evasion, and therapeutic innovation Yujia Zhu, Hongxiao Song, Fengchao Xu, Mian Huang, Guangyun Tan Frontiers in Immunology.2025;[Epub] CrossRef
Multisite Occupancy and Multidimensional Optimization: Design and Evaluation of Piperazine-Thioureidobenzamide Derivatives as Potent HBV Capsid Assembly Modulators Minghui Liang, Yutong Dou, Jian Zhang, Zechun Yang, Yuanyuan Liu, Mei Wang, Yiyan Mao, Lindan Guan, Aixin Li, Yuqing Cai, Yan Wang, Peng Xue, Lei Zhang, Zhuanchang Wu, Xinyong Liu, Peng Zhan, Haiyong Jia Journal of Medicinal Chemistry.2025; 68(22): 24358. CrossRef
Linvencovir: Paving the way for functional cure in hepatitis B Jiwon Yang, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 164. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Novel mechanistic insights – A brand new Era for anti-HBV drugs Weiping Lyu, Haoming Qin, Qi Li, Dehua Lu, Cheng Shi, Kangchen Zhao, Shengran Zhang, Ruohan Yu, Huiying Zhang, Xiaonan Zhou, Sitian Xia, Liangren Zhang, Xiaoqian Wang, Xiaowei Chi, Zhenming Liu European Journal of Medicinal Chemistry.2024; 279: 116854. CrossRef
Background/Aims Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy.
Methods We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment.
Result s: The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset.
Conclusions Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.
Citations
Citations to this article as recorded by
AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim Journal of Hepatology.2025; 82(3): 456. CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Explainable machine learning for the assessment of donor grafts in liver transplantation Liang Zhixing, Ye Linsen, Jiang Peng, Dong Siyi, Yu Haoyuan, Li Kun, Li Siqi, Hu Yongwei, Zhang Mingshen, Liu Wei, Li Hua, Yi Shuhong, Chen Guihua, Xu Xiao, Zheng Shusen, Yang Yang Hepatology Research.2025; 55(6): 908. CrossRef
Role of risk factors and their variable types in predicting noise-induced hearing loss using artificial intelligence algorithms Zhengheng Zhang, Longteng Jiang, Meibian Zhang, Yuan Pan, Jinnan Zheng, Anqi Liu, Weijiang Hu, Xin Jin Hearing Research.2025; 465: 109353. CrossRef
Artificial Intelligence and Machine Learning Applications in Liver Disease Bhargav Vemulapalli, Meghana Ghattu, Kavya Atluri, James Lee, Vinod Rustgi Clinics in Liver Disease.2025; 29(4): 755. CrossRef
Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response Aya I. Abdelaziz, Eman Abdelsameea, Sara A. Wahdan, Doaa Elsherbiny, Zeinab Zakaria, Samar S. Azab Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination Daniela Toma, Lucreția Anghel, Diana Patraș, Anamaria Ciubară Viruses.2025; 17(8): 1069. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Identifying new strategies to combat cytomegalovirus by integrating existing and innovative approaches in diagnosis and treatment Nargiz Imamova, Ayten Feteliyeva, Adil M. Allahverdiyev Future Virology.2025; 20(10): 379. CrossRef
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions Kirolos Eskandar iLIVER.2025; 4(4): 100205. CrossRef
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan Chin-Wei Chang, Wei-Fan Hsu, Kuo-Chih Tseng, Chi-Yi Chen, Pin-Nan Cheng, Chao-Hung Hung, Ching-Chu Lo, Ming-Jong Bair, Chien-Hung Chen, Pei-Lun Lee, Chun-Yen Lin, Hsing-Tao Kuo, Chun-Ting Chen, Chi-Chieh Yang, Jee-Fu Huang, Chi-Ming Tai, Jui-Ting Hu, Chih Digestive Diseases and Sciences.2024; 69(9): 3501. CrossRef
Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries Guilherme Silva Julian, Wen-Yi Shau, Hsu-Wen Chou, Sajita Setia JMIR Medical Informatics.2024; 12: e58548. CrossRef
The role of artificial intelligence in the management of liver diseases Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study Khalid M. Al-Naamani, Heba Omar, Said A. Al Busafi, Halima H. Al Shuaili, Zakariya Al-Naamani, Murtadha Al-Khabori, Elias A. Said, Abdullah H. AlKalbani, B. R. Kamath, Bashar Emad, Shahina Daar, Lolo Alhajri, Alya AlKalbani, Zainab AlFarsi, Haifa Alzuhaib Journal of Clinical Medicine.2024; 13(23): 7411. CrossRef
Background/Aims Growth hormone (GH) is the main regulator of somatic growth, metabolism, and gender dimorphism in the liver. GH receptor (GHR) signaling in cancer is derived from a large body of evidence, although the GHR signaling pathway involved in the prognosis of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related HCC, remains unclear. We aimed to explore the expression of GHR and analyze its association with clinicopathologic features and prognosis of patients with chronic hepatitis C and HCC.
Methods The expression of GHR mRNA was investigated by quantitative real-time polymerase chain reaction in paired tumors and adjacent non-tumorous (ANT) liver tissues of 200 patients with chronic hepatitis C and HCC. Western blotting and immunofluorescence assays using the HCV-infected Huh7.5.1 cell model was performed.
Result s: GHR mRNA was significantly lower in HCV-HCC tissues than in corresponding ANT liver tissues. GHR mRNA and protein levels also decreased in the HCV-infected Huh7.5.1 cell model. Notably, lower GHR expression was associated with age of >60 years (P=0.0111) and worse clinicopathologic characteristics, including alpha-fetoprotein >100 ng/mL (P=0.0403), cirrhosis (P=0.0075), vascular invasion (P=0.0052), pathological stage II–IV (P=0.0002), and albumin ≤4.0 g/dL (P=0.0055), which were linked with poor prognosis of HCC. Most importantly, the high incidence of recurrence and poor survival rates in patients with a low ratio of tumor/ANT GHR (≤0.1) were observed, indicating that low expression levels of GHR had great risk for development of HCC in patients with chronic hepatitis C.
Conclusions Our study demonstrates a significant down-regulation of GHR expression as a new unfavorable independent prognostic factor in patients with chronic hepatitis C and HCC.
Citations
Citations to this article as recorded by
Integrated Multi-Omics Analysis Reveals Cytokine Network Dynamics and Prognostic Signatures in Hepatitis B Virus-Associated Hepatocellular Carcinoma Mo-Han Liu, Fu-Yong Zhang, Yuan-Jun Huang, Zhi-Hua Jiang, Qin-Yan Chen, Lu-Juan Zhang, Li-Ping Hu, Zhong-Liao Fang Applied Biochemistry and Biotechnology.2026;[Epub] CrossRef
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies Reetobrata Basu, Cesar L Boguszewski, John J Kopchick Endocrine Reviews.2025; 46(2): 224. CrossRef
Deciphering the Oncogenic Landscape of Hepatocytes Through Integrated Single‐Nucleus and Bulk RNA‐Seq of Hepatocellular Carcinoma Huanhou Su, Xuewen Zhou, Guanchuan Lin, Chaochao Luo, Wei Meng, Cui Lv, Yuting Chen, Zebin Wen, Xu Li, Yongzhang Wu, Changtai Xiao, Jian Yang, Jiameng Lu, Xingguang Luo, Yan Chen, Paul KH Tam, Chuanjiang Li, Haitao Sun, Xinghua Pan Advanced Science.2025;[Epub] CrossRef
Multiscale identification of DNASE1L3 as a key target in MASLD progression to hepatocellular carcinoma Lintao Xia, Xiuli Yan, Hui Zhang Pathology - Research and Practice.2025; 275: 156192. CrossRef
Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy Jialin Qu, Fenghao Sun, Yichen Hou, Haoran Qi, Xiaorong Sun, Ligang Xing BMC Cancer.2023;[Epub] CrossRef
Growth hormone receptor agonists and antagonists: From protein expression and purification to long‐acting formulations Yue Wang, Minah Kim, Chantal Buckley, Heather D. Maynard, Ries J. Langley, Jo K. Perry Protein Science.2023;[Epub] CrossRef
Three E2F target-related genes signature for predicting prognosis, immune features, and drug sensitivity in hepatocellular carcinoma Baozhu Zhang, Boyang Chang, Lu Wang, Yuzhong Xu Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma Takahiro Kodama, Michiko Kodama, Nancy A. Jenkins, Neal G. Copeland, Huanhuan Joyce Chen, Zhubo Wei Cancers.2022; 14(11): 2589. CrossRef
Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma Yuanyuan Guo, Jing Yang, Hua Gao, Xin Tian, Xiaojian Zhang, Quancheng Kan Frontiers in Immunology.2022;[Epub] CrossRef
Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor Mona A. Abu El-Makarem, Mariana F. Kamel, Ahmed A. Mohamed, Hisham A. Ali, Mahmoud R. Mohamed, Alaa El-Deen M. Mohamed, Ahmed M. El-Said, Mahmoud G. Ameen, Alshymaa A. Hassnine, Hatem A. Hassan, Gianfranco D. Alpini PLOS ONE.2022; 17(11): e0277266. CrossRef
MustSeq, an alternative approach for multiplexible strand-specific 3’ end sequencing of mRNA transcriptome confers high efficiency and practicality Liyao Mai, Yinbin Qiu, Zhiwei Lian, Caiming Chen, Linlin Wang, Yao Yin, Siqi Wang, Xiang Yang, Yazi Li, Wanwan Peng, Chaochao Luo, Xinghua Pan RNA Biology.2021; 18(sup1): 232. CrossRef
Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.
Methods The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.
Result s: Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10).
Conclusions HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.
Citations
Citations to this article as recorded by
Predictive value of osteoprotegerin and heart fatty acid binding protein as biomarkers for heart failure in chronic kidney disease patients on hemodialysis: A case-control study Saddam Jaber Khudiar, Rayah Sulaiman Baban, Arif Sami Malik Journal of Research in Pharmacy.2025; 29(2): 682. CrossRef
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai Clinical and Molecular Hepatology.2025; 31(3): 899. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study Takeya Tsutsumi, Hiroshi Yotsuyanagi Kanzo.2024; 65(8): 368. CrossRef
Enhancing hepatitis C management in ESRD: Evaluating efficacy and safety of alternative antiviral regimens Ume Aiman, Umer Bin Shahzad Therapeutic Apheresis and Dialysis.2024; 28(6): 967. CrossRef
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes Ming-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, Horng-Yih Ou, Pin-Nan Cheng, Shih-Te Tu, Jee-Fu Huang, Jung-Fu Chen, Tsung-Hui Hu, Chih-Cheng Hsu, Jia-Horng Kao, Chien-Jen Chen, Han-Chieh Lin, Chien-Ning Huang Journal of the Formosan Medical Association.2023; 122(3): 202. CrossRef
Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed Oliver Scherf-Clavel Therapeutic Drug Monitoring.2022; 44(2): 253. CrossRef
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 Chen-Hua Liu, Jia-Horng Kao Hepatology International.2022; 16(5): 1001. CrossRef
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report Mario Enrico Canonico, Giuseppe Damiano Sanna, Roberta Siciliano, Fernando Scudiero, Giovanni Esposito, Guido Parodi Frontiers in Pharmacology.2022;[Epub] CrossRef
Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents Tyler Shugg, Nicholas R. Powell, Patrick J. Marroum, Todd C. Skaar, Islam R. Younis Clinical Pharmacology & Therapeutics.2022; 112(5): 1088. CrossRef
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study Vicki Wing-Ki Hui, Christopher Langjun Au, Amy Shuk Man Lam, Terry Cheuk-Fung Yip, Yee-Kit Tse, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong Hepatology International.2022; 16(6): 1318. CrossRef
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy Chung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, Yi-Wen Chiu, Ming-Lung Yu Journal of Hepatology.2021; 75(4): 1006. CrossRef
Background/Aims Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and a late call-back strategy (R.N.A. model) was applied. We aimed to compare the HCV treatment rate of patients treated with this strategy compared to those without.
Methods One hundred and twenty-five anti-HCV seropositive patients who adopted the R.N.A. model in 2020 and another 1,396 controls treated in 2019 were enrolled to compare the gaps in accurate HCV RNA diagnosis to final treatment allocation.
Result s: The HCV RNA testing rate was significantly higher in patients who received reflex testing than in those without reflex testing (100% vs. 84.8%, P<0.001). When patients were stratified according to the referring outpatient department, a significant improvement in the HCV RNA testing rate was particularly noted in patients from non-hepatology departments (100% vs. 23.3%, P<0.001). The treatment rate in HCV RNA seropositive patients was 83% (83/100) after the adoption of the R.N.A. model, among whom 96.1% and 73.9% of patients were from the hepatology and non-hepatology departments, respectively. Compared to subjects without R.N.A. model application, a significant improvement in the treatment rate was observed for patients from non-hepatology departments (73.9% vs. 27.8%, P=0.001). The application of the R.N.A. model significantly increased the in-hospital HCV treatment uptake from 6.4% to 73.9% for patients from non-hepatology departments (P<0.001).
Conclusions The care cascade increased the treatment uptake and set up a model for enhancing in-hospital HCV elimination.
Citations
Citations to this article as recorded by
Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Infection and Public Health.2026; 19(2): 103076. CrossRef
Challenges of an EMR‐Based Hospital Alert Program for Micro‐Elimination of Hepatitis C in Tertiary Referral Hospitals Hee Yeon Kim, Hae Lim Lee, Heechul Nam, Soon Kyu Lee, Ji won Han, Hyun Yang, Ahlim Lee, Pil Soo Sung, Seok‐Hwan Kim, Jihye Lim, Do Seon Song, Myeong Jun Song, Jeong Won Jang, U Im Chang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Seung Kew Yoon, Jung Hyun Journal of Viral Hepatitis.2026;[Epub] CrossRef
Real‐World Impact of a Simplified ‘Test and Treat’ Strategy for In‐Hospital HCV Micro‐Elimination Chunfang You, Yuting Diao, Juan Tang, Jing Tang, Wei Deng, Chunqi Zheng, Dongxia Liao, Dan Song, Jie Wang, Yangyang Pu Journal of Viral Hepatitis.2026;[Epub] CrossRef
Hepatitis C virus‐free endoscope procedures project: An in‐hospital elimination approach Benjamin Lih‐Ren Hsieh, Yen‐Ting Kuo, Yu‐Ju Wei, Pei‐Chien Tsai, Ming‐Lun Yeh, Chung‐Feng Huang, Chia‐Yen Dai, Ming‐Yen Hsieh, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Enhancing Hepatitis C Virus Testing, Linkage to Care, and Treatment Commencement in Hospitals: A Systematic Review and Meta-analysis Rebecca Mathews, Claudia Shen, Michael W Traeger, Helen M O’Brien, Christine Roder, Margaret E Hellard, Joseph S Doyle Open Forum Infectious Diseases.2025;[Epub] CrossRef
A Point‐of‐Care Model for Hepatitis C Elimination in Remote Islands of Taiwan Tzu‐Chun Lin, Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Ming‐Yen Hsieh, Ming‐Jong Bair, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Differences among specialists in using the Electronic Medical Record alert system for HCV screening in outpatients at a large general hospital Cheng-Kuan Lin, Yu-Sen Peng, Chi-Yu Yang, Tyng-Yuan Jang, PLOS One.2025; 20(10): e0333940. CrossRef
‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues Chia-Yen Dai, Batbold Batsaikhan, Chung-Feng Huang Journal of Hepatology.2024; 80(3): e106. CrossRef
Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan Chung‐Feng Huang, Tyng‐Yuan Jang, Shun‐Chieh Yu, Shin‐Chung Huang, Shao‐Lun Ho, Ming‐Lun Yeh, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Po‐Yao Hsu, Ching‐I Huang, Ming‐Yen Hsieh, Yi‐Hung Lin, Sung‐Lin Yu, Pey‐Fang Wu, Yu‐Han Chen, Shin‐Chi Chien, Jee‐Fu H The Kaohsiung Journal of Medical Sciences.2024; 40(1): 86. CrossRef
Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide Chi‐Ming Tai, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(2): 112. CrossRef
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city Riying Lv, Yanmeng Lu, Wenyao Xiang, Menglan Meng, Shixiong Li Journal of Viral Hepatitis.2024; 31(4): 208. CrossRef
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2024; 39(6): 1155. CrossRef
Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model Jonggi Choi, Jina Park, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sujin Kwon, Sang‐Hyun Hwang Liver International.2024; 44(5): 1243. CrossRef
Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analítica Javier Crespo, Joaquín Cabezas, Antonio Aguilera, Marina Berenguer, María Buti, Xavier Forns, Federico García, Javier García-Samaniego, Manuel Hernández-Guerra, Francisco Jorquera, Jeffrey V. Lazarus, Sabela Lens, Elisa Martró, Juan Antonio Pineda, Martín Gastroenterología y Hepatología.2023; 46(2): 150. CrossRef
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes Ming-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, Horng-Yih Ou, Pin-Nan Cheng, Shih-Te Tu, Jee-Fu Huang, Jung-Fu Chen, Tsung-Hui Hu, Chih-Cheng Hsu, Jia-Horng Kao, Chien-Jen Chen, Han-Chieh Lin, Chien-Ning Huang Journal of the Formosan Medical Association.2023; 122(3): 202. CrossRef
Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model Ching-Chu Lo, Wei-Yi Lei, Ying-Che Huang, Jow-Jyh Hwang, Chen-Yu Lo, Chien-hung Lin, Hsu-sheng Cheng, Yee-Tam Liao, Po-Cheng Liang, Meng-Jau Chiou, Ming-Jong Bair, Chia-Yen Dai, Ming-Lung Yu Journal of Microbiology, Immunology and Infection.2023; 56(4): 680. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur Scientific Reports.2023;[Epub] CrossRef
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction Javier Crespo, Joaquín Cabezas, Antonio Aguilera, Marina Berenguer, María Buti, Xavier Forns, Federico García, Javier García-Samaniego, Manuel Hernández-Guerra, Francisco Jorquera, Jeffrey V. Lazarus, Sabela Lens, Elisa Martró, Juan Antonio Pineda, Martín Gastroenterología y Hepatología (English Edition).2023; 46(2): 150. CrossRef
A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic Ching-I Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming Journal of Microbiology, Immunology and Infection.2023; 56(3): 586. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Reflex Hepatitis C Virus Viral Load Testing Following an Initial Positive Hepatitis C Virus Antibody Test: A Global Systematic Review and Meta-analysis Yusha Tao, Weiming Tang, Emmanuel Fajardo, Mengyuan Cheng, Shiyi He, Jennifer S Bissram, Lindsey Hiebert, John W Ward, Roger Chou, Francisco Rodríguez-Frías, Philippa Easterbrook, Joseph D Tucker Clinical Infectious Diseases.2023; 77(8): 1137. CrossRef
HCV Microelimination for High-risk Special Populations Chung-Feng Huang, Guan-Jhou Chen, Chien-Ching Hung, Ming-Lung Yu The Journal of Infectious Diseases.2023; 228(Supplement): S168. CrossRef
Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan Rong-Nan Chien, Sheng-Nan Lu, Grace Hui-Min Wu, Wen-Wen Yang, Raoh-Fang Pwu, Chia-Ling Liu, Kuo-Pen Cheng, Shih-Chung Chen, Chien-Jen Chen The Journal of Infectious Diseases.2023; 228(Supplement): S180. CrossRef
Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience Lingling Zheng, Xiaoli Zhang, Yuxia Nian, Wenjuan Zhou, Dan Li, Yong Wu BMC Gastroenterology.2023;[Epub] CrossRef
Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation Andrea Marcellusi, Francesco Saverio Mennini, Murad Ruf, Claudio Galli, Alessio Aghemo, Maurizia R. Brunetto, Sergio Babudieri, Antonio Craxi, Massimo Andreoni, Loreta A. Kondili Liver International.2022; 42(1): 26. CrossRef
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison Chun-Ting Chen, Ming-Ying Lu, Meng-Hsuan Hsieh, Pei-Chien Tsai, Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching-I Huang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Ye World Journal of Gastroenterology.2022; 28(2): 263. CrossRef
Micro-Elimination of Hepatitis C among Patients with Kidney Disease by Using Electronic Reminder System—A Hospital-Based Experience Pei-Yuan Su, Wei-Wen Su, Yu-Chun Hsu, Shu-Yi Wang, Ping-Fang Chiu, Hsu-Heng Yen Journal of Clinical Medicine.2022; 11(2): 423. CrossRef
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues Chia-Yen Dai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu Journal of Infection.2022; 85(4): e94. CrossRef
Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic Chi-Ming Tai, Chun-Kai Huang, Te-Chang Changchien, Po-Chun Lin, Deng-Wu Wang, Ting-Ting Chang, Hsue-Wei Chan, Tzu-Haw Chen, Cheng-Hao Tseng, Chih-Cheng Chen, Chia-Ta Tsai, Yu-Ting Sie, Yung-Chieh Yen, Ming-Lung Yu Viruses.2022; 14(8): 1637. CrossRef
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment Jonggi Choi, Jina Park, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung Gut and Liver.2022; 16(6): 964. CrossRef
How to Optimize the Care Cascade of Hepatitis C Virus Infection Beom Kyung Kim Gut and Liver.2022; 16(6): 809. CrossRef
A People-Centered Decentralized Outreach Model Toward HCV Micro-Elimination in Hyperendemic Areas: COMPACT Study in SARS Co-V2 Pandemic Ching-i Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming SSRN Electronic Journal .2022;[Epub] CrossRef
Reflex Hepatitis C Virus Viral Load Reflex Testing Following an Initial Positive Hcv Antibody Test: A Global Systematic Review and Meta-Analysis Yusha Tao, Weiming Tang, Emmanuel Fajardo, Mengyuan Cheng, Shiyi He, Jennifer S. Bissram, Lindsey Hiebert, John W. Ward, Roger Chou, Francisco Rodríguez-Frias, Philippa Easterbrook, Joseph D. Tucker SSRN Electronic Journal .2022;[Epub] CrossRef
Elimination of hepatitis C: What would be the practical approach? Hyung Joon Yim Clinical and Molecular Hepatology.2021; 27(1): 97. CrossRef
Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus—A Hospital-Based Experience Pei-Yuan Su, Yang-Yuan Chen, Hsu-Heng Yen, Siou-Ping Huang, I-Ling Liu, Ya-Huei Zeng, Yu-Chun Hsu, Fu-Yuan Siao Journal of Clinical Medicine.2021; 10(11): 2509. CrossRef
Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study Hsu-Heng Yen, Pei-Yuan Su, I.-L.ing Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Po-Ke Hsu, Yang-Yuan Chen BMC Gastroenterology.2021;[Epub] CrossRef
First
Prev
